Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effect of Knee Position on Muscle Loss During Leg Immobilization

10 de novembro de 2026 atualizado por: Marlou Dirks, Wageningen University

A Novel Angle: Manipulating Knee Position to Understand Muscle Deterioration During Leg Immobilization

This study looks at what happens to leg muscles when the knee is kept straight or bent during five days of wearing a brace. We want to find out if keeping the knee bent (so the thigh muscle is stretched) helps prevent muscle loss compared to keeping the knee straight. Thirty healthy adults will take part. They will wear a knee brace for five days and have several tests before and after, including scans, blood samples, and small muscle samples. The results may help doctors find better ways to protect muscles when people cannot move, for example after surgery or illness.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Short periods of physical inactivity, as occur during illness, surgery, or injury, lead to rapid and substantial losses of muscle mass, strength, and metabolic health, often with incomplete recovery in vulnerable individuals. In older adults, repeated bouts of disuse are thought to contribute significantly to age-related sarcopenia. Despite decades of research, the underlying mechanisms remain incompletely elucidated, and effective therapeutic interventions are lacking.

Mechanistically, any muscle atrophy must occur due to a negative muscle protein net balance (MPNB), which can be caused by a decline in muscle protein synthesis (MPS), an increase in muscle protein breakdown (MPB), or a combination of both. Normally, exercise and dietary protein stimulate MPS and maintain muscle mass. During disuse, however, exercise is often impossible, and inactive muscle shows a blunted response to dietary protein. Consequently, these potent strategies become ineffective or even harmful in inactive individuals, highlighting the need for alternative approaches.

Animal studies indicate that immobilizing a muscle in a lengthened (stretched) position can attenuate disuse-induced muscle atrophy and functional decline compared to a shortened position. Whether this phenomenon also occurs in humans, and whether passive muscle length and tension influence muscle metabolism during disuse, remain unexplored.

The objective of this study is to assess whether immobilizing the quadriceps in a lengthened versus neutral position during disuse attenuates losses of muscle mass, function, and metabolic health.

In this randomized, controlled human intervention study with 2 parallel groups 30 healthy, normal weight males and females (18-40 years old, BMI between 18 and 30 kg·m-2) will undergo 5 days of unilateral leg immobilization using a knee brace that prevents voluntary quadriceps contraction. In the neutral group, the leg is fixed in full extension (0° flexion), while in the lengthened group it is fixed at 60° flexion, stretching the quadriceps.

The effects on muscle protein net balance (MPNB), quadriceps muscle volume , muscle quality, muscle strength, fatigue resistance, and muscle mitochondrial bioenergetics will be assessed.

Tipo de estudo

Intervencional

Inscrição (Estimado)

30

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Wageningen, Holanda, 6708 WD
        • Recrutamento
        • Wageningen University and Research
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 40 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Healthy males and females
  • Aged from 18-40 years at the time of signing informed consent
  • 18.5 < BMI < 30 kg·m-2
  • Must be willing and able to communicate and participate in the whole study

Exclusion Criteria:

  • Smoking
  • Diabetes (Type 1, Type 2, or genetic form of diabetes)
  • Any diagnosed cardiovascular (heart) disease or high blood pressure (≥140 mmHg systolic and/or ≥90 mmHg diastolic)
  • Chronic use of any prescribed or over the counter pharmaceuticals that may modulate muscle protein metabolism (excluding oral contraceptives and contraceptive devices).
  • A personal or family history of thrombosis, epilepsy, seizures or schizophrenia.
  • Prone to keloid forming (i.e. hyperplastic growth of scars).
  • Any known disorders in muscle metabolism
  • Regular use of dietary protein and/or amino acid supplements (>3 times per week)
  • Currently involved in a structured progressive resistance training programme (>3 times per week)
  • Known allergy to lidocaine
  • Known severe kidney problems
  • Allergy to one or multiple amino acids
  • Recent (within the last 6 months) or current musculoskeletal injury (e.g. leg fracture)
  • Having received or ingested a stable isotope tracer containing 15N in the past
  • Contra-indications for MRI such as incompatible metal objects in the body and claustrophobia.
  • Currently taking part in other scientific research
  • Pregnant or breastfeeding
  • Unable to give consent

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Neutral Knee Position

Participants in this group wear a knee brace in full extension (0°) for five consecutive days.

Unilateral knee immobilization at 0° flexion for 5 days using a brace; post-immobilization metabolic testing with tracer infusions and biopsies

Experimental: Flexed Knee Position

Participants in this group wear a knee brace in flexion (60°) for five consecutive days.

Unilateral knee immobilization at 60° flexion for 5 days using a brace; post-immobilization metabolic testing with tracer infusions and biopsies

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Muscle protein net balance (MPNB)
Prazo: Baseline to 3 hours after tracer infusion

Muscle protein net balance expressed as %/h and calculated as the difference between muscle protein synthesis (MPS; fractional synthesis rate, FSR) and muscle protein breakdown (MPB; fractional breakdown rate, FBR), measured in skeletal muscle following 5 days of unilateral knee immobilization

Baseline to 3 hours after tracer infusion

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Thigh muscle volume
Prazo: Baseline and after 5 days of immobilization

Thigh muscle volume, including muscle length and cross-sectional area, measured via Magnetic Resonance Imaging (MRI)

Baseline and after 5 days of immobilization
Muscle strength
Prazo: Baseline and after 5 days of immobilization

Maximal voluntary muscle strength measured as peak torque using isokinetic dynamometry

Baseline and after 5 days of immobilization
Muscle fatigue
Prazo: Baseline and after 5 days of immobilization

Muscle fatigue assessed as decline in force during repeated contractions measured using isokinetic dynamometry

Baseline and after 5 days of immobilization
Intramuscular fat content
Prazo: Baseline and after 5 days of immobilization

Intramuscular lipid content measured using 1H-magnetic resonance spectroscopy (1H-MRS)

Baseline and after 5 days of immobilization
Muscle metabolite concentrations
Prazo: Baseline and after 5 days of immobilization

Carnosine and acetylcarnitine concentrations in skeletal muscle measured using 1H-magnetic resonance spectroscopy (1H-MRS)

Baseline and after 5 days of immobilization
Mitochondrial respiration
Prazo: Baseline and after 5 days of immobilization

Mitochondrial respiration measured as oxygen consumption in permeabilized muscle fibres using high-resolution respirometry

Baseline and after 5 days of immobilization
Mitochondrial reactive oxygen species production
Prazo: Baseline and after 5 days of immobilization

Mitochondrial reactive oxygen species (ROS) production measured using fluorescence-based detection in permeabilized muscle fibres

Baseline and after 5 days of immobilization
Mitochondrial calcium retention capacity
Prazo: Baseline and after 5 days of immobilization

Calcium retention capacity measured in permeabilized muscle fibres using fluorescence-based assays

Baseline and after 5 days of immobilization
Muscle gene expression related to atrophy
Prazo: Baseline and after 5 days of immobilization

Expression of genes involved in muscle atrophy measured in skeletal muscle biopsy samples using molecular analysis techniques (e.g. qPCR or RNA sequencing)

Baseline and after 5 days of immobilization
Muscle protein markers of atrophy
Prazo: Baseline and after 5 days of immobilization

Protein expression of markers related to muscle protein synthesis and breakdown measured in skeletal muscle biopsy samples

Baseline and after 5 days of immobilization

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Height
Prazo: Baseline (pre-intervention)

Height measured in meters

Baseline (pre-intervention)
Plasma amino acid concentration
Prazo: Baseline to 3 hours after tracer infusion

Plasma concentration of amino acids measured in venous blood samples

Baseline to 3 hours after tracer infusion
Serum insulin concentration
Prazo: Baseline and up to 3 hours after tracer infusion

Serum insulin concentration measured in venous blood samples

Baseline and up to 3 hours after tracer infusion
Body weight
Prazo: Baseline (pre-intervention)

Body weight measured in kilograms

Baseline (pre-intervention)
Body mass index (BMI)
Prazo: Baseline (pre-intervention)

Body mass index calculated as kg/m²

Baseline (pre-intervention)
Body composition
Prazo: Baseline (pre-intervention)

Fat mass and lean mass measured using DXA

Baseline (pre-intervention)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de agosto de 2026

Conclusão Primária (Estimado)

1 de março de 2028

Conclusão do estudo (Estimado)

1 de junho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

17 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de julho de 2026

Primeira postagem (Real)

8 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NL010759

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .